SerenQ Retatrutide Pen (20 & 40mg)

SerenQ Pharmaceuticals builds research grade retatrutide into a sealed, pre-filled injection pen rather than a lyophilised vial with a separate bacteriostatic water ampoule. No reconstitution, no working out volumes from a concentration, no drawing up with a syringe barrel. Dial the units, read them off the window, done.

Available in 20mg and 40mg strengths, both delivered in the same 300 unit pen format so the only variable is concentration per unit. Select your strength above. SerenQ has appointed The Ped Shop as its exclusive UK stockist. Every pen sold here comes direct from the manufacturer, in sealed retail cartons, with a unique serial number and QR authenticity code on the label.

Two strengths, one pen format

Choose your strength above

SerenQ Pharmaceuticals

RETATRUTIDE

Triple Agonist · Pre-filled Pen 20mg Content20mg Dial graduation15u = 1mg Per unit66.7mcg Total units300u FormatPre-filled pen Pen tips32G 0.23 x 4mm Expiry12/2027 AuthenticityQR + serial SerenQ Pharmaceuticals

RETATRUTIDE

Triple Agonist · Pre-filled Pen 40mg Content40mg Dial graduation15u = 2mg Per unit133mcg Total units300u FormatPre-filled pen Pen tips32G 0.23 x 4mm Expiry12/2027 AuthenticityQR + serial

Third Party Testing

Results pending

Every SerenQ batch is sent for independent analysis before it goes on general sale. Purity, identity and potency testing for this batch is currently with Analiza, and the certificate will be published on this page the moment it lands.

LaboratoryAnaliza TestPurity, identity, potency MethodHPLC / MS / bioassay StatusAwaiting report

Check back here for the full certificate, or ask us and we will send it over as soon as it is released.

Serialised & QR Verified

Every SerenQ product carries a unique serial number and a QR code printed on the label. Scan it with any phone camera and you can independently confirm the pen is genuine SerenQ stock and check its batch details before you open the carton.

One code per pen. Each one can only be registered once, so a duplicate scan is an immediate red flag.

About the compound

Retatrutide is a synthetic, long-acting peptide agonist that binds three separate incretin receptors at once: the GLP-1 receptor, the GIP (glucose-dependent insulinotropic polypeptide) receptor, and the glucagon receptor. That third receptor is what separates it from the previous generation of agonists in the class. Semaglutide targets GLP-1 alone. Tirzepatide targets GLP-1 and GIP together. Retatrutide adds glucagon on top, making it the first triple agonist to enter late stage clinical development.

Structurally it is a 39 amino acid peptide, engineered from a GIP backbone with substitutions and a fatty acid moiety attached via a linker for reversible albumin binding. That albumin binding is what carries the plasma half-life out to approximately 6 days, making weekly dosing the operating assumption in the published trials.

Each receptor pulls in a different direction in the research literature. GLP-1 activation drives glucose dependent insulin secretion, suppresses glucagon in the fed state, delays gastric emptying, and modulates hypothalamic satiety signalling. GIP activation adds a separate insulinotropic route via pancreatic beta cells and appears to influence adipose tissue metabolism. Glucagon receptor activation, counter-intuitive in a compound aimed at metabolic control, adds a thermogenic and lipolytic dimension via hepatic and adipose tissue signalling. In Phase II data published to date, the combined effect on body weight and adiposity has consistently outperformed both single and dual agonists tested in matched cohorts.

Research applications span glycaemic control, body weight and adiposity, appetite regulation, energy expenditure and hepatic lipid handling. Both the 20mg and 40mg pens deliver the same molecule at the same 300 unit graduation, so the only variable across the two is concentration per unit.

Where the evidence sits: retatrutide is a novel investigational compound currently in Phase III clinical trials. It is not licensed as a medicinal product in the UK, the US or any other jurisdiction, has no approved clinical indication, and is not commercially available in any prescription form. It is supplied here strictly as a laboratory research chemical.

The pen format

Both strengths use the same pen platform. Instead of a lyophilised vial that has to be reconstituted with bacteriostatic water, calculated for concentration and drawn up with a syringe, the retatrutide arrives pre-dissolved in a stabilised solution and pre-loaded into a graduated injection pen with a dial and a dose window. Every dial setting delivers a consistent, verifiable volume.

20mg pen

• 20mg of retatrutide per pen, pre-dissolved in solution
• 1 unit = 66.7mcg
• 15 units on the dial gives 1mg
• 300 units in total, which works out at 20 full 15 unit draws per pen

40mg pen

• 40mg of retatrutide per pen, pre-dissolved in solution
• 1 unit = 133mcg
• 15 units on the dial gives 2mg
• 300 units in total, which works out at 20 full 15 unit draws per pen

Shared across both strengths

• Dial and dose window let you set the exact amount and read it back before dispensing
• 4 screw on pen tips supplied, individually sealed, 32G 0.23 x 4mm
• 4 alcohol swabs supplied
• Protective cap, clip and a rigid retail carton for storage and transport
• Batch number, expiry and serial printed directly on the pen barrel, not just the box

Handling and storage

• Store refrigerated at 2 to 8°C. Do not freeze
• Keep in the outer carton, away from direct light
• Solution should be clear and colourless. Discard if cloudy, discoloured or if particulates are visible
• Short periods at room temperature during transit are expected and normal, though prolonged exposure will degrade potency
• Use a fresh sealed tip for each dispense and dispose of tips in a sharps container
• Expiry 12/2027 on sealed, correctly stored stock
• Keep out of reach of children and animals

What is in the box

• 1 × SerenQ Retatrutide pre-filled injection pen (20mg or 40mg per your selection above)
• 4 × sealed pen tips, 32G 0.23 x 4mm
• 4 × alcohol swabs
• Serialised, QR coded retail carton

For research purposes only

This product is sold strictly as a laboratory research chemical. It is not a medicine, not a supplement and not a cosmetic. It is not for human or veterinary consumption, and it is not intended to diagnose, treat, cure or prevent any disease or condition.

Retatrutide is a novel investigational compound in Phase III clinical development. It is not authorised by the MHRA, the FDA or any other medicines regulator, has no approved clinical indication, and is not available in any licensed prescription form. Nothing on this page should be read as medical advice, a recommendation, or a suggestion of use in humans or animals.

By purchasing you confirm you are 18 or over, that you are acquiring this product for legitimate laboratory research or analytical use only, and that you accept full responsibility for its safe handling, storage and lawful use under the regulations that apply where you are.